Free Trial
NASDAQ:IXHL

Incannex Healthcare Q3 2025 Earnings Report

Incannex Healthcare logo
$0.18 +0.00 (+0.17%)
Closing price 06/6/2025 04:00 PM Eastern
Extended Trading
$0.18 +0.00 (+0.95%)
As of 06/6/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Incannex Healthcare EPS Results

Actual EPS
-$0.24
Consensus EPS
-$0.46
Beat/Miss
Beat by +$0.22
One Year Ago EPS
N/A

Incannex Healthcare Revenue Results

Actual Revenue
$0.10 million
Expected Revenue
$0.16 million
Beat/Miss
Missed by -$57.00 thousand
YoY Revenue Growth
N/A

Incannex Healthcare Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Thursday, May 15, 2025
Conference Call Time
9:30AM ET

Earnings Documents

Incannex Healthcare Earnings Headlines

Cannabis Stocks To Add to Your Watchlist - May 29th
"I'm risking my reputation on this"
Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the same signals. They're positioning themselves for something unprecedented. And after 17 million podcast downloads and over 600 insider interviews, I finally connected all the dots… What I discovered was so explosive, so potentially life-changing, that I had to put it all in a book.
Cannabis Stocks To Consider - May 28th
See More Incannex Healthcare Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Incannex Healthcare? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Incannex Healthcare and other key companies, straight to your email.

About Incannex Healthcare

Incannex Healthcare (NASDAQ:IXHL), a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury and concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, suppoCan gastro for IBD, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. Incannex Healthcare Inc. was incorporated in 2001 and is based in Sydney, Australia.

View Incannex Healthcare Profile

More Earnings Resources from MarketBeat